Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 8/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CSF1R | P07333 | 1/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 4/20 | 0.39 |
| ▸ | TDO2 | P48775 | 4/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.37 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.37 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.37 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.37 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.37 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1230439 | 0.91 | SCD (0.67) | SCDCSF1RPDGFRBKITDDR1 | |
| SCHEMBL10276168 | 0.86 | SCD (0.64) | SCDCSF1RPDGFRBKITDDR1 | |
| SCHEMBL10276483 | 0.86 | SCD (0.64) | SCDCSF1RPDGFRBKITDDR1 | |
| SCHEMBL1230469 | 0.86 | SCD (0.64) | SCD | |
| SCHEMBL1231030 | 0.82 | SCD (0.54) | SCDCSF1RPDGFRBKITDDR1 | |
| SCHEMBL1231219 | 0.81 | SCD (0.49) | SCD | |
| SCHEMBL1231168 | 0.80 | SCD (0.53) | SCD | |
| SCHEMBL1231576 | 0.80 | SCD (0.65) | SCD | |
| SCHEMBL1229316 | 0.80 | SCD (0.65) | SCD | |
| SCHEMBL1231573 | 0.80 | SCD (0.65) | SCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2462121-B1 | DERIVATIVES OF 2H PYRIDAZIN-3-ONES, THEIR PREPARATION AND THEIR USE AS SCD-1 INHIBITORS | PF MEDICAMENT (FR) | 2015-02-18 | — | — | EP | claimed |
| US-8946225-B2 | Derivatives of 2H pyridazin-3-ones, their preparation and their use as SCD-1 inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2015-02-03 | — | — | US | claimed |
| US-20120178678-A1 | DERIVATIVES OF 2H PYRIDAZIN- 3 -ONES, THEIR PREPARATION AND THEIR USE AS SCD-1 INHIBITORS | PIERRE FABRE MEDICAMENT (FR) | 2012-07-12 | — | — | US | claimed |
| EP-2462121-A1 | DERIVATIVES OF 2H PYRIDAZIN- 3 -ONES, THEIR PREPARATION AND THEIR USE AS SCD-1 INHIBITORS | Pierre Fabre Médicament (FR) | 2012-06-13 | — | — | EP | claimed |
| WO-2011015629-A1 | DERIVATIVES OF 2H PYRIDAZIN- 3 -ONES, THEIR PREPARATION AND THEIR USE AS SCD-1 INHIBITORS | PIERRE FABRE MEDICAMENT (FR) | 2011-02-10 | — | — | WO | claimed |
| EP-2462121-B1 | DERIVATIVES OF 2H PYRIDAZIN-3-ONES, THEIR PREPARATION AND THEIR USE AS SCD-1 INHIBITORS | PF MEDICAMENT (FR) | 2015-02-18 | — | — | EP | disclosed |
| EP-2462121-B1 | DERIVATIVES OF 2H PYRIDAZIN-3-ONES, THEIR PREPARATION AND THEIR USE AS SCD-1 INHIBITORS | PF MEDICAMENT (FR) | 2015-02-18 | — | — | EP | disclosed |
| US-8946225-B2 | Derivatives of 2H pyridazin-3-ones, their preparation and their use as SCD-1 inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2015-02-03 | — | — | US | disclosed |
| US-8946225-B2 | Derivatives of 2H pyridazin-3-ones, their preparation and their use as SCD-1 inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2015-02-03 | — | — | US | disclosed |
| US-8946225-B2 | Derivatives of 2H pyridazin-3-ones, their preparation and their use as SCD-1 inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2015-02-03 | — | — | US | disclosed |
| US-20120178678-A1 | DERIVATIVES OF 2H PYRIDAZIN- 3 -ONES, THEIR PREPARATION AND THEIR USE AS SCD-1 INHIBITORS | PIERRE FABRE MEDICAMENT (FR) | 2012-07-12 | — | — | US | disclosed |
| US-20120178678-A1 | DERIVATIVES OF 2H PYRIDAZIN- 3 -ONES, THEIR PREPARATION AND THEIR USE AS SCD-1 INHIBITORS | PIERRE FABRE MEDICAMENT (FR) | 2012-07-12 | — | — | US | disclosed |
| US-20120178678-A1 | DERIVATIVES OF 2H PYRIDAZIN- 3 -ONES, THEIR PREPARATION AND THEIR USE AS SCD-1 INHIBITORS | PIERRE FABRE MEDICAMENT (FR) | 2012-07-12 | — | — | US | disclosed |
| EP-2462121-A1 | DERIVATIVES OF 2H PYRIDAZIN- 3 -ONES, THEIR PREPARATION AND THEIR USE AS SCD-1 INHIBITORS | Pierre Fabre Médicament (FR) | 2012-06-13 | — | — | EP | disclosed |
| WO-2011015629-A1 | DERIVATIVES OF 2H PYRIDAZIN- 3 -ONES, THEIR PREPARATION AND THEIR USE AS SCD-1 INHIBITORS | PIERRE FABRE MEDICAMENT (FR) | 2011-02-10 | — | — | WO | disclosed |
| WO-2011015629-A1 | DERIVATIVES OF 2H PYRIDAZIN- 3 -ONES, THEIR PREPARATION AND THEIR USE AS SCD-1 INHIBITORS | PIERRE FABRE MEDICAMENT (FR) | 2011-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178678-A1 | DERIVATIVES OF 2H PYRIDAZIN- 3 -ONES, THEIR PREPARATION AND THEIR USE AS SCD-1 INHIBITORS | SCD, SCD5, CYP2S1 | SCD 1/4885ALDH1A1 319/4885CSF1R 584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.